KDC-MN-125 – Kodiac biolabs

Plain-language summaryIntrigue 65 / 100

Davunetide (NAP) is an 8-amino-acid peptide derived from activity-dependent neuroprotective protein (ADNP). It supports microtubule integrity in neurons. Phase 2/3 trials in progressive supranuclear palsy were inconclusive. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

44/100

Interesting ADNP-derived tau biology probe that failed its pivotal PSP trial but retains real bench utility

Look, the honest framing on davunetide is this: it had a serious shot, it swung, and it missed. Allon Therapeutics ran a genuine pivotal trial in progressive supranuclear palsy, a devastating tauopathy with almost no treatment options, and the 2012 primary cognitive endpoint came back negative. The development program was shuttered. That’s not a single-lab anecdote gone sideways; thats a well-resourced Phase 2/3 effort that produced a definitive answer for the PSP indication. Researchers need to hold that fact in one hand before they do anything else with this compound.

The underlying biology is a different story, and it’s genuinely worth knowing. Davunetide is an eight-amino-acid fragment of ADNP, activity-dependent neuroprotective protein, which is a zinc-finger protein with a critical SIP box motif that interacts directly with microtubule-end binding proteins. The idea is that NAP stabilizes EB1/EB3-tubulin interactions and in doing so slows the hyperphosphorylation and aggregation of tau. That’s a plausible and fairly specific mechanism. Multiple labs, not just the originating Gozes group in Tel Aviv, have reproduced effects in rodent tauopathy models, including APP-PSEN1 mice and P301L transgenic lines. The preclinical corpus is solid enough to take seriously.

What we find interesting right now is the ADNP syndrome angle. ADNP haploinsufficiency causes a syndromic intellectual disability with autistic features, and the field has produced a handful of publications over the past three years examining whether NAP peptide can rescue ADNP-syndrome mouse phenotypes. The Gozes lab has continued publishing in this direction, and there are now independent replication attempts from other groups. It’s early, the N is tiny, and we haven’t seen a structured human signal, but the translational question is at least reformulated in a way that isn’t capped by the PSP failure.

As a bench tool, davunetide has real value for anyone studying microtubule dynamics in neurons, tau biology, or ADNP-interactome questions. The intranasal delivery pharmacokinetics are unusually well-characterized for a research peptide, partly because of the clinical program. Researchers have a reasonably solid CNS exposure profile to work from. Sourcing is more accessible than it was, and the peptide is structurally simple enough that vendor quality is easier to verify by HPLC than for larger fragments.

We dont think this belongs near the top of anyone’s list unless they’re specifically working the ADNP biology or designing tauopathy assays that need a reasonably specific microtubule-protective control. For those investigators, its genuinely useful. For everyone else, the failed pivotal trial is load-bearing information and the translational arrow is, at best, pointing sideways.

Novelty: 48
Mechanism promise: 52
In-category differentiation: 38
Evidence quality: 48
Translational signal: 28
Research bench value: 50

Rationale Davunetide scores modestly across the board because its development program ended on a clean negative result in a well-powered Phase 2/3 PSP trial (2012), crushing its translational signal even though the preclinical mechanistic work is real and multi-lab. What keeps it from falling further is the renewed relevance of ADNP biology through ADNP syndrome research and the compound’s continued utility as a probe for microtubule dynamics and tau pathology in preclinical models.

ADNP-derived octapeptide

An eight-amino-acid fragment of activity-dependent neuroprotective protein (ADNP) studied in tauopathies and PSP.

Abstract

Davunetide (NAP, AL-108; Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln; CAS 173308-60-2; molecular weight 824.94) is an octapeptide derived from activity-dependent neuroprotective protein (ADNP). The peptide preserves microtubule integrity and reduces tau pathology in animal models of tauopathy. Davunetide was developed by Allon Therapeutics and advanced through Phase 2/3 trials in progressive supranuclear palsy (PSP); the pivotal trial in 2012 was negative for the primary cognitive endpoint, ending the development program. The compound is administered intranasally (the primary route of delivery to CNS for the formulation used in trials). Research-grade doses are 5 to 30 mg intranasally per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-125Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-125

Davunetide (NAP)

Abstract

Read the full monograph